External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

July 30, 2023

Study Completion Date

March 24, 2024

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

177Lu-DOTA-TLX591

TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)

Trial Locations (4)

GenesisCare Tugun, Tugun

GenesisCare St Andrews, Adelaide

GenesisCare Murdoch, Perth

GenesisCare North Shore, St Leonards

All Listed Sponsors

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY